Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Arrhythmias

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 166 articles:
HTML format
Text format



Single Articles


    March 2017
  1. RAHIMI K
    Subclinical atrial fibrillation in need of more assertive evidence.
    Eur Heart J. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    



  2. Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS'.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  3. CAMM AJ, Savelieva I
    Female gender as a risk factor for stroke associated with atrial fibrillation.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  4. LUSCHER TF
    Atrial fibrillation and thrombo- embolism: anticoagulants or devices?
    Eur Heart J. 2017;38:839-842.
    PubMed     Text format    


  5. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  6. VAN GELDER IC, Healey JS, Crijns HJ, Wang J, et al
    Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
    Eur Heart J. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  7. SHUN-SHIN MJ, Zheng SL, Cole GD, Howard JP, et al
    Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.
    Eur Heart J. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. AKDIS D, Saguner AM, Shah K, Wei C, et al
    Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.
    Eur Heart J. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. BACANOVIC S, Steffen C, Benz DC, Kaufmann PA, et al
    Third-degree atrioventricular block: tip of the iceberg of a systemic disease.
    Eur Heart J. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


    January 2017
  10. GADSBOLL K, Staerk L, Fosbol EL, Sindet-Pedersen C, et al
    Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.
    Eur Heart J. 2017 Jan 21. pii: ehw658. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. SCHWARTZ PJ
    Evolving concepts for the Long QT Syndrome.
    Eur Heart J. 2017;38:225-226.
    PubMed     Text format    


  12. STEFFEL J
    The Subcutaneous Implantable Cardioverter Defibrillator.
    Eur Heart J. 2017;38:226-228.
    PubMed     Text format    


  13. MCLEOD CJ, Boersma L, Okamura H, Friedman PA, et al
    The subcutaneous implantable cardioverter defibrillator: state-of-the-art review.
    Eur Heart J. 2017;38:247-257.
    PubMed     Text format    


  14. ARBELO E, Brugada J, Lundqvist CB, Laroche C, et al
    Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry.
    Eur Heart J. 2017 Jan 18. pii: ehw564. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. RENOUX C, Coulombe J, Suissa S
    Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study.
    Eur Heart J. 2017 Jan 10. pii: ehw613. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    


  17. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
    Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
    Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. FANOLA CL, Giugliano RP, Ruff CT, Trevisan M, et al
    A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
    Eur Heart J. 2017 Jan 6. pii: ehw565. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. SCHMIDT C, Wiedmann F, Zhou XB, Heijman J, et al
    Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Eur Heart J. 2017 Jan 4. pii: ehw559. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. NATTEL S
    Close connections between contraction and rhythm: a new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us.
    Eur Heart J. 2017;38:35-37.
    PubMed     Text format    


  21. GRACE A, Verma A, Willems S
    Dipole Density Mapping of Atrial Fibrillation.
    Eur Heart J. 2017;38:5-9.
    PubMed     Text format    


  22. LIP GY
    Stroke prevention in Atrial Fibrillation.
    Eur Heart J. 2017;38:4-5.
    PubMed     Text format    


  23. LUSCHER TF
    Atrial fibrillation beyond the arrhythmia: hypercoagulability, adipose tissue, and fibrotic remodelling.
    Eur Heart J. 2017;38:1-3.
    PubMed     Text format    


    December 2016
  24. NYNS EC, Kip A, Bart CI, Plomp JJ, et al
    Optogenetic termination of ventricular arrhythmias in the whole heart: towards biological cardiac rhythm management.
    Eur Heart J. 2016 Dec 23. pii: ehw574. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. DURU F, Brunckhorst C
    Zurich International Symposium on Arrhythmogenic Right Ventricular Cardiomyopathies.
    Eur Heart J. 2016;37:3555-3556.
    PubMed     Text format    


  26. WAHBI K, Babuty D, Probst V, Wissocque L, et al
    Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  27. WAHBI K, Babuty D, Probst V, Wissocque L, et al
    Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.
    Eur Heart J. 2016 Dec 9. doi: 10.1093.
    PubMed     Text format    


    October 2016
  28. HALVORSEN S, Storey RF, Rocca B, Sibbing D, et al
    Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.
    Eur Heart J. 2016.
    PubMed     Text format    


  29. TARANTINI G, Mojoli M, Urena M, Vahanian A, et al
    Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  30. GUDBJARTSSON DF, Holm H, Sulem P, Masson G, et al
    A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  31. STAERK L, Fosbol EL, Lip GY, Lamberts M, et al
    Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available



  32. Yoga and atrial fibrillation.
    Eur Heart J. 2016;37:2855.
    PubMed     Text format    



  33. 'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation.
    Eur Heart J. 2016;37:2853.
    PubMed     Text format    



  34. What's new in the 2016 ESC Guidelines on atrial fibrillation?
    Eur Heart J. 2016;37:2851-2852.
    PubMed     Text format    


  35. LUSCHER TF
    Atrial fibrillation: today's guideline-based management.
    Eur Heart J. 2016;37:2847-2850.
    PubMed     Text format    


    September 2016
  36. IBRAHIM T, Dommasch M, Huber A, Hoppmann P, et al
    Percutaneous revascularization of concurrently obstructed left-sided pulmonary veins complicating catheter ablation for atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format    


  37. ZAMORANO JL
    Specific risk of atrial fibrillation and stroke in oncology patients.
    Eur Heart J. 2016;37:2747-2748.
    PubMed     Text format    


  38. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    


    August 2016
  39. KIRCHHOF P, Benussi S, Kotecha D, Ahlsson A, et al
    2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the Eur
    Eur Heart J. 2016.
    PubMed     Text format    


  40. LUSCHER TF
    Atrial fibrillation and stroke: risk factors, anticoagulation, and left atrial appendage occluders.
    Eur Heart J. 2016;37:2443-5.
    PubMed     Text format    


    July 2016
  41. BUNCH TJ, May HT
    Atrial fibrillation: a risk factor or risk marker?
    Eur Heart J. 2016.
    PubMed     Text format    


  42. LAU DH, Middeldorp ME, Sanders P
    Obesity paradox in atrial fibrillation: a distracting reality or fictitious finding?
    Eur Heart J. 2016.
    PubMed     Text format    


  43. KIRCHHOF P, Calkins H
    Catheter ablation in patients with persistent atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  44. KUCK KH, Furnkranz A, Chun KR, Metzner A, et al
    Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    June 2016
  45. BASSAND JP, Accetta G, Camm AJ, Cools F, et al
    Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  46. HEIDBUCHEL H, Verhamme P, Alings M, Antz M, et al
    Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  47. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
    Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    May 2016
  48. LUSCHER TF
    Atrial fibrillation: novel risk factors, mechanisms and ablation techniques.
    Eur Heart J. 2016;37:1553-5.
    PubMed     Text format    


    April 2016
  49. BADIMON L, Cubedo J
    Hypercoagulability and atrial fibrillation: a two-way road?
    Eur Heart J. 2016.
    PubMed     Text format    


  50. SPRONK HM, De Jong AM, Verheule S, De Boer HC, et al
    Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  51. SANDHU RK, Ezekowitz J, Andersson U, Alexander JH, et al
    The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  52. NIELSEN JC, Gerdes JC
    Does catheter ablation reduce mortality and stroke in patients with atrial fibrillation? Patient selection or causality?
    Eur Heart J. 2016.
    PubMed     Text format    


  53. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Eur Heart J. 2016;37:1015-23.
    PubMed     Text format    


    March 2016
  54. YOSHINAGA M, Kucho Y, Nishibatake M, Ogata H, et al
    Probability of diagnosing long QT syndrome in children and adolescents according to the criteria of the HRS/EHRA/APHRS expert consensus statement.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  55. CAIRNS JA
    The search for the ideal atrial fibrillation stroke risk prediction schema: is ATRIA a contender?
    Eur Heart J. 2016.
    PubMed     Text format    


  56. CHEN Y, Zheng M, Lin K, Cui K, et al
    Mapping and surgical ablation of persistent atrial fibrillation in cor triatriatum sinister.
    Eur Heart J. 2016.
    PubMed     Text format    


  57. FRIBERG L, Tabrizi F, Englund A
    Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  58. FOX KA
    CardioPulse: Anticoagulants reduce risk of death in atrialfibrillation patients by 38%.
    Eur Heart J. 2016;37:860-1.
    PubMed     Text format    


  59. MORSETH B, Graff-Iversen S, Jacobsen BK, Jorgensen L, et al
    Physical activity, resting heart rate, and atrial fibrillation: the Tromso Study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  60. ASPBERG S, Chang Y, Atterman A, Bottai M, et al
    Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  61. WONG CX, Ganesan AN, Selvanayagam JB
    Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  62. DILLER GP, Brautigam A, Kempny A, Uebing A, et al
    Depression requiring anti-depressant drug therapy in adult congenital heart disease: prevalence, risk factors, and prognostic value.
    Eur Heart J. 2016;37:771-82.
    PubMed     Text format     Abstract available


    February 2016
  63. HIJAZI Z, Lindback J, Alexander JH, Hanna M, et al
    The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  64. SOTO-RUIZ RM, Bonaque Gonzalez JC, Fernandez Gasso L, Castillo Moreno JA, et al
    Persistent mitral and tricuspid insufficiency.
    Eur Heart J. 2016;37:712.
    PubMed     Text format    


  65. GANESAN AN, Chew DP, Hartshorne T, Selvanayagam JB, et al
    The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available



  66. CardioPulse: Ear stimulation for atrial fibrillation favoured at ESC Congress London.
    Eur Heart J. 2016;37:586.
    PubMed     Text format    


  67. TRUCHANOWICZ E, Kirchhof P
    CardioPulse: New perspectives for stroke prevention in atrial fibrillation.
    Eur Heart J. 2016;37:583-4.
    PubMed     Text format    


  68. TOFIELD A
    CardioPulse: Syncope and near drowning may signal sudden death risk.
    Eur Heart J. 2016;37:585.
    PubMed     Text format    


  69. OZKAN J
    CardioPulse: Gerhard Hindricks MD.
    Eur Heart J. 2016;37:580-1.
    PubMed     Text format    


  70. LUSCHER TF
    Managing arrhythmias: diagnosis and modern treatment.
    Eur Heart J. 2016;37:577-9.
    PubMed     Text format    


  71. STEFFEL J, Jais P, Hindricks G
    The year in cardiology 2015: arrhythmias and device therapy.
    Eur Heart J. 2016;37:587-93.
    PubMed     Text format    


  72. TANAWUTTIWAT T, Nazarian S, Calkins H
    The role of catheter ablation in the management of ventricular tachycardia.
    Eur Heart J. 2016;37:594-609.
    PubMed     Text format     Abstract available


  73. ANNEKEN L, Baumann S, Vigneault P, Biliczki P, et al
    Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking.
    Eur Heart J. 2016;37:640-50.
    PubMed     Text format     Abstract available


  74. KAMAKURA T, Wada M, Nakajima I, Ishibashi K, et al
    Significance of electrocardiogram recording in high intercostal spaces in patients with early repolarization syndrome.
    Eur Heart J. 2016;37:630-7.
    PubMed     Text format     Abstract available


  75. KOCH J, Lucke C, Gebauer R, Hindricks G, et al
    Accessory pathway ablation in childhood forming the substrate for ventricular tachycardia in adulthood.
    Eur Heart J. 2016;37:609.
    PubMed     Text format    


  76. STROKER E, de Asmundis C, Chierchia GB, Brugada P, et al
    Exercise-related Brugada pattern and monomorphic ventricular tachycardia in a patient with Brugada syndrome: interplay between body temperature, haemodynamics and vagal activity.
    Eur Heart J. 2016;37:655.
    PubMed     Text format    


  77. WEBB J, Frigiola A, Carr-White G, Chiribiri A, et al
    An unusual cause of ventricular tachycardia.
    Eur Heart J. 2016;37:654.
    PubMed     Text format    


  78. VEHMEIJER JT, Brouwer TF, Limpens J, Knops RE, et al
    Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  79. AUER J
    Fat: an emerging player in the field of atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format    


  80. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  81. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  82. SINGH SM, d'Avila A, Kim YH, Aryana A, et al
    The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study).
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  83. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
    Eur Heart J. 2016 Feb 4. doi: 10.1093.
    PubMed     Text format    


  84. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
    Eur Heart J. 2016 Feb 4. doi: 10.1093.
    PubMed     Text format    


  85. AQUILA I, Garcia A, Fernandez-Golfin C, Zamorano JL, et al
    It paces right but not in the right space!
    Eur Heart J. 2016;37:496.
    PubMed     Text format    


    January 2016
  86. VERHEUGT FW
    CardioPulse: Triple therapy for percutaneous coronary intervention in atrial fibrillation: a nightmare.
    Eur Heart J. 2016;37:326-7.
    PubMed     Text format    


  87. POZZOLI A, Mazzone P, Benussi S, Alfieri O, et al
    Incomplete surgical exclusion of the left atrial appendage.
    Eur Heart J. 2016;37:188.
    PubMed     Text format    


    December 2015
  88. AMIN AS, Wilde AA
    Genetic screening in acquired long QT syndrome? CAUTION: proceed carefully.
    Eur Heart J. 2015.
    PubMed     Text format    


  89. ITOH H, Crotti L, Aiba T, Spazzolini C, et al
    The genetics underlying acquired long QT syndrome: impact for genetic screening.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  90. LUSCHER TF
    Supraventricular and ventricular arrhythmias.
    Eur Heart J. 2015;36:3215-7.
    PubMed     Text format    


    November 2015
  91. HAEMERS P, Hamdi H, Guedj K, Suffee N, et al
    Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  92. LAU DH, Schotten U, Mahajan R, Antic NA, et al
    Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  93. CONTE G, Regoli F, Moccetti T, Auricchio A, et al
    Subcutaneous implantable cardioverter-defibrillator and drug-induced Brugada syndrome: the importance of repeat morphology analysis during ajmaline challenge.
    Eur Heart J. 2015.
    PubMed     Text format    


    October 2015
  94. MCLEOD CJ, Boersma L, Okamura H, Friedman PA, et al
    The subcutaneous implantable cardioverter defibrillator: state-of-the-art review.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  95. SCOTT LR
    Antiarrhythmic drugs after ablation for atrial fibrillation: the hope, the hype, and the reality.
    Eur Heart J. 2015.
    PubMed     Text format    


    September 2015
  96. O'BRIEN EC, Simon DN, Thomas LE, Hylek EM, et al
    The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  97. KOTECHA D, Piccini JP
    Atrial fibrillation in heart failure: what should we do?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  98. KAITANI K, Inoue K, Kobori A, Nakazawa Y, et al
    Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  99. GAL P, Marrouche NF
    Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  100. FOX K, Ford I, Steg PG, Tardif JC, et al
    Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  101. JARED BUNCH T
    One drug, two outcomes after atrial fibrillation ablation: the situational irony of adenosine.
    Eur Heart J. 2015.
    PubMed     Text format    


  102. AZARBAL F, Stefanick ML, Assimes TL, Manson JE, et al
    Lean body mass and risk of incident atrial fibrillation in post-menopausal women.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  103. NALLIAH CJ, Sanders P, Kottkamp H, Kalman JM, et al
    The role of obesity in atrial fibrillation.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  104. VINEREANU D, Stevens SR, Alexander JH, Al-Khatib SM, et al
    Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  105. LIP GY
    The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history.
    Eur Heart J. 2015.
    PubMed     Text format    


  106. LIP GY, Lane DA
    Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors.
    Eur Heart J. 2015.
    PubMed     Text format    


  107. TAYLOR J
    Uninterrupted novel oral anticoagulant therapy during atrial fibrillation ablation is safe.
    Eur Heart J. 2015;36:2272.
    PubMed     Text format    


  108. CAMM AJ, Amarenco P, Haas S, Hess S, et al
    XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    August 2015
  109. KOBORI A, Shizuta S, Inoue K, Kaitani K, et al
    Adenosine triphosphate-guided pulmonary vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  110. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
    Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  111. PRIORI SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, et al
    2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Eu
    Eur Heart J. 2015.
    PubMed     Text format    


  112. GALIE N, Humbert M, Vachiery JL, Gibbs S, et al
    2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)End
    Eur Heart J. 2015.
    PubMed     Text format    


  113. TE RIELE AS, James CA, Groeneweg JA, Sawant AC, et al
    Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  114. WEIR RA, Murphy CA, O'Rourke B, Petrie CJ, et al
    Twiddler's syndrome: a rare cause of implantable cardioverter defibrillator malfunction.
    Eur Heart J. 2015.
    PubMed     Text format    


  115. GORCSAN J 3RD, Schwartzman D
    Ventricular arrhythmias after cardiac resynchronization therapy: does reverse remodelling reverse risk?
    Eur Heart J. 2015.
    PubMed     Text format    


  116. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
    Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  117. TOFIELD A
    Digoxin mortality in heart failure and atrial fibrillation.
    Eur Heart J. 2015;36:1944-5.
    PubMed     Text format    


  118. POTPARA TS, Lip GY
    Patterns in atrial fibrillation management and 'real-world' adherence to guidelines in the Balkan Region: an overview of the Balkan-atrial fibrillation survey.
    Eur Heart J. 2015;36:1943-4.
    PubMed     Text format    


  119. LUSCHER TF
    Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
    Eur Heart J. 2015;36:1937-9.
    PubMed     Text format    


  120. FANG Z, Zeng L, Chen Y, Cui K, et al
    Paroxysmal atrial fibrillation originating from giant right atrial appendage aneurysm.
    Eur Heart J. 2015.
    PubMed     Text format    


    July 2015
  121. CORRADO D, Wichter T, Link MS, Hauer R, et al
    Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
    Eur Heart J. 2015.
    PubMed     Text format    


  122. BUDJAN J, Haghi D, Henzler T, Papavassiliu T, et al
    Myocardial herniation in constrictive pericarditis mimicking arrhythmogenic right ventricular cardiomyopathy.
    Eur Heart J. 2015.
    PubMed     Text format    


  123. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
    Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  124. GHOUSE J, Have CT, Weeke P, Bille Nielsen J, et al
    Rare genetic variants previously associated with congenital forms of long QT syndrome have little or no effect on the QT interval.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  125. LUSCHER TF
    Mitral valve disease, atrial fibrillation, and device therapy.
    Eur Heart J. 2015;36:1631-3.
    PubMed     Text format    


    June 2015
  126. BANSCH D, Bonnemeier H, Brandt J, Bode F, et al
    Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  127. LIMA DA SILVA G, Pinto FJ, Almeida AG
    Invasive cardiac aspergillosis presenting as complete heart block in a patient with acute lymphoblastic leukaemia.
    Eur Heart J. 2015;36:1555.
    PubMed     Text format    


  128. LUSCHER TF
    Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation.
    Eur Heart J. 2015;36:1415-7.
    PubMed     Text format    


  129. SHARMA S, Merghani A, Mont L
    Exercise and the heart: the good, the bad, and the ugly.
    Eur Heart J. 2015;36:1445-53.
    PubMed     Text format     Abstract available


  130. POKORNEY SD, Granger CB
    Should patients on vitamin K antagonists be treated differently?
    Eur Heart J. 2015;36:1431-3.
    PubMed     Text format    


  131. O'DONOGHUE ML, Ruff CT, Giugliano RP, Murphy SA, et al
    Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationdagger.
    Eur Heart J. 2015;36:1470-7.
    PubMed     Text format     Abstract available


  132. HANSEN BJ, Zhao J, Csepe TA, Moore BT, et al
    Atrial fibrillation driven by micro-anatomic intramural re-entry revealed by simultaneous sub-epicardial and sub-endocardial optical mapping in explanted human hearts.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  133. KACZMAREK KA, Winter J, Wranicz JK, Ptaszynski PA, et al
    Atypical position of subcutaneus implantable cardioverter-defibrillator as a solution in hypertrophic cardiomyopathy patient with initially negative electrocardiographic screening.
    Eur Heart J. 2015.
    PubMed     Text format    


  134. HOLZHAUSER L, Heymer J, Kasner M, Landmesser U, et al
    Rare case of a multilocular primary cardiac intimal sarcoma presenting as left atrial mass with new onset atrial fibrillation.
    Eur Heart J. 2015.
    PubMed     Text format    


  135. ZAIDI A, Sharma S
    Arrhythmogenic right ventricular remodelling in endurance athletes: Pandora's box or Achilles' heel?
    Eur Heart J. 2015.
    PubMed     Text format    


  136. LA GERCHE A, Claessen G, Dymarkowski S, Voigt JU, et al
    Exercise-induced right ventricular dysfunction is associated with ventricular arrhythmias in endurance athletes.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  137. SEMSARIAN C, Ingles J, Wilde AA
    Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives.
    Eur Heart J. 2015;36:1290-6.
    PubMed     Text format     Abstract available


  138. ROELL W, Sinning JM, Werner N, Mellert F, et al
    How to re-shape a transcatheter heart valve.
    Eur Heart J. 2015;36:1287.
    PubMed     Text format    


    May 2015
  139. MONT L
    Atrial fibrillation ablation: less is more?
    Eur Heart J. 2015.
    PubMed     Text format    


  140. BREITHARDT G, Baumgartner H
    Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term.
    Eur Heart J. 2015.
    PubMed     Text format    


  141. PHILIPPART R, Brunet-Bernard A, Clementy N, Bourguignon T, et al
    Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  142. CAPPATO R, Marchlinski FE, Hohnloser SH, Naccarelli GV, et al
    Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  143. STEFFEL J, Giugliano RP, Braunwald E, Murphy SA, et al
    Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  144. CORRADO D, Zorzi A
    Arrhythmogenic right ventricular cardiomyopathy and sports activity.
    Eur Heart J. 2015.
    PubMed     Text format    


  145. BAUERSACHS J, Hilfiker-Kleiner D, Veltmann C
    Underestimated risk for life-threatening ventricular arrhythmias in newly diagnosed peripartum cardiomyopathy?
    Eur Heart J. 2015;36:1067-8.
    PubMed     Text format    


  146. SAYED RH, Rogers D, Khan F, Wechalekar AD, et al
    A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.
    Eur Heart J. 2015;36:1098-105.
    PubMed     Text format     Abstract available


    April 2015
  147. LUSCHER TF
    Arrhythmias, syncopy, and sudden death.
    Eur Heart J. 2015;36:829-31.
    PubMed     Text format    


  148. VENTECLEF N, Guglielmi V, Balse E, Gaborit B, et al
    Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines.
    Eur Heart J. 2015;36:795-805a.
    PubMed     Text format     Abstract available


    March 2015
  149. LUSCHER TF
    Heart failure: focus on co-morbidities, inflammation, and heart rate.
    Eur Heart J. 2015;36:635-7.
    PubMed     Text format    


  150. GLUKHOV AV, Kalyanasundaram A, Lou Q, Hage LT, et al
    Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1.
    Eur Heart J. 2015;36:686-97.
    PubMed     Text format     Abstract available


  151. COTTENS D, Corteville B, Vanvinckenroye A, Schepens M, et al
    Moderate gradient with disproportional dyspnoea: multimodality imaging of funnel-shaped subaortic membrane.
    Eur Heart J. 2015;36:583.
    PubMed     Text format    


    February 2015
  152. LUBITZ SA, Singh JP
    Biventricular pacing: more is better!
    Eur Heart J. 2015;36:407-9.
    PubMed     Text format    


  153. ALIOT E, Brandes A, Eckardt L, Elvan A, et al
    The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial.
    Eur Heart J. 2015;36:255-6.
    PubMed     Text format    


  154. LUSCHER TF
    Arrhythmias and device therapy.
    Eur Heart J. 2015;36:253-4.
    PubMed     Text format    


  155. HEIDBUCHEL H, Hindricks G
    The year in cardiology 2014: arrhythmias and device therapy.
    Eur Heart J. 2015;36:270-8.
    PubMed     Text format     Abstract available


    January 2015
  156. LUSCHER TF
    Arrhythmias and pacing.
    Eur Heart J. 2015;36:131-2.
    PubMed     Text format    


  157. MURAKOSHI N, Xu D, Sairenchi T, Igarashi M, et al
    Prognostic impact of supraventricular premature complexes in community-based health checkups: the Ibaraki Prefectural Health Study.
    Eur Heart J. 2015;36:170-8.
    PubMed     Text format     Abstract available


  158. HEIDBUCHEL H, Hindricks G, Broadhurst P, Van Erven L, et al
    EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring.
    Eur Heart J. 2015;36:158-69.
    PubMed     Text format     Abstract available


  159. STOCKBURGER M, Boveda S, Moreno J, Da Costa A, et al
    Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.
    Eur Heart J. 2015;36:151-7.
    PubMed     Text format     Abstract available


  160. BOGDAN S, Glikson M
    Physiological pacing: a moving target?
    Eur Heart J. 2015;36:141-2.
    PubMed     Text format    


    October 2014
  161. PELLICORI P, Zhang J, Lukaschuk E, Joseph AC, et al
    Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    August 2014
  162. GORENEK B
    Pre-hospital care: a critical phase of the acute cardiovascular care management process.
    Eur Heart J. 2014;35:2125-6.
    PubMed     Text format    


  163. YOUSSEF AA, Wilbring M, Laniado M, Kappert U, et al
    Like a dented bumper: a heart impressed by a giant left atrial appendage in a 22-year-old patient.
    Eur Heart J. 2014;35:2057.
    PubMed     Text format    


  164. SENNI M, Paulus WJ, Gavazzi A, Fraser AG, et al
    New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    July 2014
  165. BAX JJ, Delgado V, Bapat V, Baumgartner H, et al
    Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    May 2014
  166. MELENOVSKY V, Hwang SJ, Lin G, Redfield MM, et al
    Right heart dysfunction in heart failure with preserved ejection fraction.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: